- Russia has strongly denied new allegations that claim Russian spies stole a “blueprint” for the Oxford-AstraZeneca vaccine and used it to make its Sputnik V shot.
- The head of Russia’s sovereign wealth fund called the claims “scientific nonsense”.
- New reports appeared in the British press this week alleging that UK security services told ministers they had evidence that Russia stole blueprints.
Russia has strongly denied new allegations, claiming Russian spies stole a “blueprint” for the Oxford-AstraZeneca vaccine and using it as “scientific nonsense” claims the head of Russia’s sovereign wealth fund To make my own Sputnik V shot.
There have been fresh reports in the British press this week alleging that UK security services told British ministers they had solid evidence that Russia stole a British-made vaccine template and used it to make Sputnik V. did.
Sun The tabloid newspaper first reported the allegations made by British security services, although Downing Street declined to comment. This is not the first time that Russia has been accused of trying to steal and hack Covid vaccine data, but Moscow has repeatedly denied the allegations, with the RDIF calling the latest report “fake” and “false”. Is.
The head of the country’s sovereign wealth fund, RDIF, echoed that sentiment on Wednesday, calling the allegations “scientific nonsense”.
“There is no qualification [to these claims] And we are very clear about that,” Kirill Dmitriev told CNBC on Wednesday. “This report is complete scientific nonsense, has zero merit and is clearly a lie.”
Calling the report “nonsense from unnamed sources”, Dmitriev said the latest allegations were part of “a smear campaign against Sputnik V” because some politicians don’t like Russia and some big pharma companies, who are affected by the success of Sputnik V. Afraid, keep attacking Sputnik V and Sputnik Light [its one-dose booster shot] From day one, so we’re used to these attacks,” he told CNBC’s “Street Signs Europe.”
Dmitriev stressed that the developers behind Sputnik V want to partner with other vaccine producers and cited a joint clinical trial with AstraZeneca. (To determine if a mixed covid vaccine works), “We believe in a joint approach to working with other vaccine producers and Sputnik V is a partner for other vaccines.”
The Russian Direct Investment Fund, or RDIF, is one of the world’s leading sovereign funds with a reserve capital of $10 billion under management. The fund supported the development of Russia’s main coronavirus vaccine, Sputnik V, the world’s first COVID vaccine to be authorized by Russia in August 2020.
The Sputnik V vaccine has been the subject of doubt – firstly over its clinical data and efficacy – and, most recently, over its origin and development.
Interim analysis of Phase 3 clinical trials of SHOT, Covered 20,000 participants and published in the peer-reviewed medical journal The Lancet In early February, it was found that it was 91.6% effective against symptomatic COVID-19 infection.
Nevertheless, the vaccine is not authorized for use by pharmaceutical authorities in the US, UK and EU. The World Health Organization has said it is still assessing the vaccine, but has not indicated when and if it may give the shot an emergency use list.
Not to be disappointed, Russia has developed several other COVID vaccines and has since worked on a one-shot “Sputnik Lite” vaccine designed to be used as a booster shot. in August, RDIF said Sputnik Lite was “proven to be highly effective against COVID in over 320,000 subjects who received the vaccine based on data collected as of July 30, 2021.” It cited an efficacy rate of 93.5%.
RDIF’s Dmitriev told CNBC that Russia expects to have the Sputnik V vaccine approved by the end of 2021 and hopes the one-shot Sputnik Lite can soon be used as a booster shot with other vaccines. Is.
“We’ve seen a lot of positive signals from WHO recently and they really appreciate what we’re doing… ‘Sputnik Lite’ can be a booster for other vaccines like AstraZeneca and Moderna among many others , so we believe in a very positive solution with WHO as soon as the fall … of course we expect an approval very soon,” he said.